close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Announces New Data to be Presented on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
Calidi Biotherapeutics Announces Establishment of Scientific Advisory Board to Support Development of CLD-401 and Advance its RedTail Platform for the Systemic Delivery of Targeted Genetic Medicine
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
Calidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in Boston
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
Calidi Biotherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on July 24
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
Calidi Biotherapeutics Announces Shareholder Letter from CEO
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
Calidi Biotherapeutics Presents systemic oncolytic platform with CD55-Enhanced expression and IL-15 Superagonist Payload at ASCO Annual Meeting
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
Calidi Biotherapeutics Announces IL15 Superagonist as First Payload to be Delivered by Systemic Antitumor Virotherapy  Platform at AACR Annual Meeting
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
Tickers MTEM
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
Calidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid Tumors
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
Calidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
Calidi Biotherapeutics and City of Hope Provide Update on a Phase 1 Clinical Trial with CLD-101 Virotherapy in Patients with Recurrent High-Grade Glioma
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
Calidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic Platform
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
Calidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University Hospital
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
Calidi Biotherapeutics Announces Presentation of New Data of Systemic Virotherapy RTNova Platform at the AACR Annual Meeting in April 2025
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today